Carisbamate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Carisbamate
Accession Number
DB12338
Type
Small Molecule
Groups
Investigational
Description

Carisbamate has been investigated in Alcohol Abuse, Substance Abuse, and Alcohol Dependence.

Structure
Thumb
Synonyms
Not Available
External IDs
JNJ-10234094 / RWJ-333369-000 / YKP-509
Categories
UNII
P7725I9V3Z
CAS number
194085-75-1
Weight
Average: 215.63
Monoisotopic: 215.0349209
Chemical Formula
C9H10ClNO3
InChI Key
OLBWFRRUHYQABZ-MRVPVSSYSA-N
InChI
InChI=1S/C9H10ClNO3/c10-7-4-2-1-3-6(7)8(12)5-14-9(11)13/h1-4,8,12H,5H2,(H2,11,13)/t8-/m1/s1
IUPAC Name
(2S)-2-(2-chlorophenyl)-2-hydroxyethyl carbamate
SMILES
NC(=O)OC[C@@H](O)C1=CC=CC=C1Cl

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Carisbamate is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3-isobutyl-1-methyl-7H-xanthineCarisbamate may increase the excretion rate of 3-isobutyl-1-methyl-7H-xanthine which could result in a lower serum level and potentially a reduction in efficacy.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Carisbamate.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Carisbamate.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Carisbamate is combined with 5-methoxy-N,N-dimethyltryptamine.
6-O-benzylguanineCarisbamate may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy.
7-DeazaguanineCarisbamate may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Carisbamate.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Carisbamate.
7,9-DimethylguanineCarisbamate may increase the excretion rate of 7,9-Dimethylguanine which could result in a lower serum level and potentially a reduction in efficacy.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
6918474
PubChem Substance
347828597
ChemSpider
5293671
ChEBI
135966
ChEMBL
CHEMBL2087003
ZINC
ZINC000030691363
Wikipedia
Carisbamate
ATC Codes
N03AX19 — Carisbamate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingBasic ScienceLennox Gastaut Syndrome / Lennox-Gastaut Syndrome (LGS)2
1, 2Active Not RecruitingOtherAlcohol Abuse / Alcohol Dependence / Substance Abuse1
2CompletedTreatmentDiabetic Mononeuropathy / Diabetic Neuropathy, Painful / Diabetic Polyneuropathy / Neuralgia, Diabetic1
2CompletedTreatmentDiabetic Neuropathies1
2CompletedTreatmentEssential Tremor, Movement Disorders1
2CompletedTreatmentHerpes Zoster / Neuralgia / Postherpetic Neuralgia1
3CompletedTreatmentComplex Partial Seizures / Epilepsies / Epilepsy, Complex Partial / Epilepsy, Localization Related1
3CompletedTreatmentEpilepsy, Complex Partial / Epilepsy, Partial, Motor / Epilepsy, Simple Partial / Focal Motor Epilepsy2
3TerminatedTreatmentEpilepsies / Seizures1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.15 mg/mLALOGPS
logP0.94ALOGPS
logP1.29ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)13.43ChemAxon
pKa (Strongest Basic)-3.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area72.55 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity51.47 m3·mol-1ChemAxon
Polarizability20.38 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Chlorobenzenes
Alternative Parents
Aryl chlorides / Carbamate esters / Secondary alcohols / Organonitrogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Aromatic alcohols
Substituents
Chlorobenzene / Aryl chloride / Aryl halide / Carbamic acid ester / Secondary alcohol / Alcohol / Aromatic alcohol / Hydrocarbon derivative / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 16:00 / Updated on March 01, 2020 21:10

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates